Zai Lab (ZLAB) Competitors $32.37 -0.11 (-0.34%) As of 12:45 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ZLAB vs. VTRS, ASND, RDY, QGEN, BBIO, MRNA, VRNA, ELAN, ROIV, and RVMDShould you be buying Zai Lab stock or one of its competitors? The main competitors of Zai Lab include Viatris (VTRS), Ascendis Pharma A/S (ASND), Dr. Reddy's Laboratories (RDY), QIAGEN (QGEN), BridgeBio Pharma (BBIO), Moderna (MRNA), Verona Pharma PLC American Depositary Share (VRNA), Elanco Animal Health (ELAN), Roivant Sciences (ROIV), and Revolution Medicines (RVMD). These companies are all part of the "pharmaceutical products" industry. Zai Lab vs. Its Competitors Viatris Ascendis Pharma A/S Dr. Reddy's Laboratories QIAGEN BridgeBio Pharma Moderna Verona Pharma PLC American Depositary Share Elanco Animal Health Roivant Sciences Revolution Medicines Viatris (NASDAQ:VTRS) and Zai Lab (NASDAQ:ZLAB) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, dividends, media sentiment, valuation and analyst recommendations. Does the media refer more to VTRS or ZLAB? In the previous week, Zai Lab had 10 more articles in the media than Viatris. MarketBeat recorded 12 mentions for Zai Lab and 2 mentions for Viatris. Viatris' average media sentiment score of 1.46 beat Zai Lab's score of 0.47 indicating that Viatris is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viatris 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zai Lab 3 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts recommend VTRS or ZLAB? Viatris currently has a consensus price target of $10.40, suggesting a potential upside of 4.07%. Zai Lab has a consensus price target of $56.35, suggesting a potential upside of 74.65%. Given Zai Lab's stronger consensus rating and higher probable upside, analysts clearly believe Zai Lab is more favorable than Viatris.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Viatris 2 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.80Zai Lab 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.86 Which has better valuation & earnings, VTRS or ZLAB? Zai Lab has lower revenue, but higher earnings than Viatris. Zai Lab is trading at a lower price-to-earnings ratio than Viatris, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioViatris$14.74B0.79-$634.20M-$2.90-3.45Zai Lab$427.80M8.43-$257.10M-$2.04-15.82 Is VTRS or ZLAB more profitable? Viatris has a net margin of -24.57% compared to Zai Lab's net margin of -49.68%. Viatris' return on equity of 16.54% beat Zai Lab's return on equity.Company Net Margins Return on Equity Return on Assets Viatris-24.57% 16.54% 7.06% Zai Lab -49.68%-27.32%-18.85% Which has more volatility & risk, VTRS or ZLAB? Viatris has a beta of 0.93, indicating that its stock price is 7% less volatile than the S&P 500. Comparatively, Zai Lab has a beta of 1.04, indicating that its stock price is 4% more volatile than the S&P 500. Do institutionals and insiders have more ownership in VTRS or ZLAB? 79.9% of Viatris shares are owned by institutional investors. Comparatively, 41.7% of Zai Lab shares are owned by institutional investors. 0.1% of Viatris shares are owned by company insiders. Comparatively, 5.0% of Zai Lab shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. SummaryZai Lab beats Viatris on 9 of the 16 factors compared between the two stocks. Get Zai Lab News Delivered to You Automatically Sign up to receive the latest news and ratings for ZLAB and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ZLAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ZLAB vs. The Competition Export to ExcelMetricZai LabMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.61B$3.18B$5.80B$10.16BDividend YieldN/A2.32%5.69%4.61%P/E Ratio-15.8321.4874.7325.99Price / Sales8.43301.34470.3491.76Price / CashN/A45.3337.0859.91Price / Book4.209.6312.256.31Net Income-$257.10M-$53.32M$3.28B$270.66M7 Day Performance4.89%0.95%1.39%3.52%1 Month Performance-5.96%9.68%7.70%6.79%1 Year Performance56.55%13.38%64.01%28.29% Zai Lab Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ZLABZai Lab2.8044 of 5 stars$32.37-0.3%$56.35+74.1%+50.6%$3.62B$427.80M-15.871,869Gap UpVTRSViatris1.5982 of 5 stars$10.55+1.3%$10.40-1.4%-10.3%$12.30B$14.74B-3.6432,000Positive NewsASNDAscendis Pharma A/S3.1082 of 5 stars$194.27+0.2%$243.36+25.3%+75.0%$11.89B$393.54M-37.651,017Positive NewsRDYDr. Reddy's Laboratories2.4707 of 5 stars$14.20-0.1%$16.95+19.4%-7.1%$11.86B$3.81B21.5127,811Positive NewsQGENQIAGEN4.468 of 5 stars$46.53+0.9%$49.69+6.8%+3.3%$10.34B$1.98B27.495,765Positive NewsBBIOBridgeBio Pharma4.3393 of 5 stars$51.76-1.5%$62.18+20.1%+87.9%$9.89B$221.90M-12.66400Positive NewsAnalyst ForecastMRNAModerna4.5036 of 5 stars$24.09-1.6%$42.88+78.0%-68.1%$9.37B$3.24B-3.205,800Positive NewsVRNAVerona Pharma PLC American Depositary Share2.1761 of 5 stars$105.91+0.0%$109.00+2.9%+252.9%$9.16B$42.28M-106.9830Positive NewsELANElanco Animal Health2.6536 of 5 stars$18.38-0.4%$17.33-5.7%+29.8%$9.12B$4.44B21.379,000Positive NewsHigh Trading VolumeROIVRoivant Sciences2.8286 of 5 stars$11.93-0.1%$16.50+38.3%+16.4%$8.15B$29.05M-17.04860News CoveragePositive NewsOptions VolumeRVMDRevolution Medicines4.2667 of 5 stars$37.97-0.9%$69.92+84.2%+11.0%$7.10B$11.58M-8.44250Trending NewsAnalyst ForecastAnalyst Revision Related Companies and Tools Related Companies Viatris Alternatives Ascendis Pharma A/S Alternatives Dr. Reddy's Laboratories Alternatives QIAGEN Alternatives BridgeBio Pharma Alternatives Moderna Alternatives Verona Pharma PLC American Depositary Share Alternatives Elanco Animal Health Alternatives Roivant Sciences Alternatives Revolution Medicines Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ZLAB) was last updated on 9/12/2025 by MarketBeat.com Staff From Our PartnersOne tiny company just cracked Google’s $19B problemCurrently, a brand-new, all-American factory outside San Antonio is becoming the most significant site in the ...True Market Insiders | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredTrump’s Plan May Undo 1933’s Biggest Financial InjusticeTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAlert: Prepare for Trump's Dollar OverhaulPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zai Lab Limited Unsponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Zai Lab With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ZLAB Stock Alerts